Robust activation of mTOR (mammalian target of rapamycin) signaling in diabetes
exacerbates myocardial injury following lethal ischemia due to accelerated cardiomyocyte …

Aims Deregulation of mTOR (mammalian target of rapamycin) signalling occurs in diabetes,
which exacerbates injury following myocardial infarction (MI). We therefore investigated the …

Diabetic patients suffer augmented severity of myocardial infarction. Excessive activation of
the mammalian target of rapamycin (mTOR) and decreased activation of STAT3 are …

Persistent activation of mTOR (mammalian target of rapamycin) in diabetes increases the
vulnerability of the heart to ischemia/reperfusion (I/R) injury. We show here that infusion of …

Background and Purpose Enhanced mammalian target of rapamycin (mTOR) signalling
contributes to the pathogenesis of diabetes and plays a critical role in myocardial …

Elevated mammalian target of rapamycin (mTOR) signaling contributes to the pathogenesis
of diabetes, with increased morbidity and mortality, mainly because of cardiovascular …

Diabetes is comorbid with cardiovascular disease and impaired immunity. Rapamycin
improves cardiac functions and extends lifespan by inhibiting the mechanistic target of …

Prompt coronary reperfusion is the gold standard for minimizing injury following acute
myocardial infarction. Rapamycin, mammalian target of Rapamycin (mTOR) inhibitor, exerts …

The progressive loss of cardiomyocytes caused by cell death leads to cardiac dysfunction
and heart failure (HF). Rapamycin has been shown to be cardioprotective in pressure …

Objectives: The extent of adverse myocardial remodeling contributes essentially to the
prognosis after myocardial infarction (MI). In this study we investigated whether inhibition of …